[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"veterans\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:veterans":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,92,120,149,179,209],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100609805","virtual-reality-lethal-means-safety-training-100609805",false,"NCT07219355","Virtual Reality Lethal Means Safety Training","Expanding Provider Capacity to Prevent Rural Veteran Suicide: Virtual Reality Lethal Means Safety Training","Inclusion Criteria:\n\n* Age 18 or older\n* healthcare providers serving rural Veterans in Texas (e.g., physicians, physician assistants, nurse practitioners, nurses, pharmacists, social workers, healthcare case managers)\n* English-speaking\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Self-reported pregnancy\n* History of motor or balance disorders\n* Color blindness\n* Neurological or cognitive disorders\n* Cardiovascular issues that may be worsened by VR use\n* Use of cardiac pacemakers, defibrillators, or hearing aids incompatible with VR equipment\n* Significant discomfort in virtual reality environments (e.g., severe motion sickness, vertigo)",true,"ALL","18 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this randomized clinical trial is to determine whether a virtual reality (VR) training program can help healthcare providers improve their skills in discussing suicide prevention and safe storage of firearms and medications with Veterans. The study will test whether VR training increases providers' self-efficacy, confidence, and comfort in conducting lethal means safety counseling, and whether it improves their intention to use these counseling practices in their clinical work. Researchers will compare healthcare providers who complete the VR training to those who complete a 2D video training to determine whether the VR approach is more effective. Participants will complete online surveys before and after the training and again three months later. They will be randomly assigned to one of two groups: VR training group: Participants use a VR headset to interact with a virtual Veteran patient in a simulated rural clinic and practice suicide prevention counseling skills; Video training group: Participants use the same headset to watch a \\~10-minute 2D video depicting the lethal means safety counseling session. After the training, participants will also provide feedback about their experience, including how realistic and useful they found the training.",[27,28,29,30,31,32],"Suicide, Attempted","Suicide, Completed","Suicide Prevention","Mental Health Training","Rural Health","Veterans",[32,34,29,35,36,37,38,39,40,31],"Rural Veterans","Suicide Risk","Firearm Safety","Medication Safety","Lethal Means Safety Counseling","Virtual Reality (VR)","VR Training Simulation","RECRUITING","2026-06-23",{"date":44,"type":45},"2026-06-24","ACTUAL",{"date":47,"type":45},"2026-02-23",{"date":49,"type":21},"2026-09-30",{"name":51,"class":52},"The University of Texas at Arlington","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100590357","phase-4-varenicline-for-smoking-reduction-in-veterans-not-ready-to-quit-100590357","NCT06966362","Varenicline for Smoking Reduction in Veterans Not Ready To Quit","Varenicline for Smoking Reduction in Veterans Unwilling to Quit","Inclusion Criteria:\n\n* Report smoking an average of 5 or more cigarettes daily for the previous 6 months\n* Not ready to set a quit date in the next 30 days but willing to cut down on their smoking\n* Able to read, write, and speak English\n* Be medically eligible to use study medications (NRT or varenicline)\n* If female, use an approved method of birth control while using study medication\n* Be at least 21 years old\n* Be a Veteran\n\nExclusion Criteria:\n\n* Unable to give informed, voluntary consent to participate\n* Current use of any pharmacotherapy for smoking cessation\n* Use of non-cigarette tobacco products as primary form of tobacco use\n* Incarceration","21 Years",{"count":63,"type":21},400,[65],"PHASE4","In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that healthcare providers offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.",[32,68,69,70],"Tobacco Use Disorder","Cigarette Smoking","Tobacco Dependence",[72,73,32,74,75,76,77,78,79],"Varenicline","Tobacco use disorder","Quit attempts","Cigarette smoking","Motivation phase treatment","Nicotine replacement therapy","Smoking reduction","Smoking abstinence","NOT_YET_RECRUITING","2026-06-18",{"date":83,"type":45},"2026-06-22",{"date":85,"type":21},"2026-07-20",{"date":87,"type":21},"2030-06-28",{"name":89,"class":90},"VA Office of Research and Development","FED",4,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":109,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":53},"100515759","a-mixed-methods-pilot-trial-of-the-step-home-workshop-to-improve-reintegration-and-reduce-suicide-risk-for-recently-transitioned-veterans-100515759","NCT05995678","A Mixed Methods Pilot Trial of the STEP Home Workshop to Improve Reintegration and Reduce Suicide Risk for Recently Transitioned Veterans","SH-SP","Inclusion Criteria:\n\n* Recently transitioned Veterans within three years of separation from military service\n* Self-reported functional impairment or reintegration difficulties as measured by the Military-to-Civilian Questionnaire (any item score \\> 1 indicating \"some difficulty\"; M2CQ; \\[71\\])\n* Sufficient English fluency\n* Agree to participate (informed consent\u002FHIPAA)\n\nExclusion Criteria:\n\n* Active psychosis\n* Imminent or acute high suicide risk requiring immediate crisis intervention (low-moderate non-imminent risk for suicide is allowed)\n* Current moderate or severe substance use disorder\n* Neurological diagnosis excluding TBI\n\n  * Participants with mild substance use disorder will be allowed\n  * Substance use is a common behavior that may contribute to reintegration difficulties and suicide risk","65 Years",{"count":101,"type":21},120,[24],"Risk of Veteran suicide is elevated during the first year of transition from military service to civilian life. Most Veteran suicides occur among Veterans who are not connected to VA healthcare. Suicide prevention and connection to care are therefore critical for recently transitioning Veterans. Transitioning Veterans require services to provide them with suicide prevention education, skills to manage their transition effectively, and support in their access to VA healthcare. Convenient, accessible, palatable, patient-centered care options that are cost-effective, easy to implement nationwide, and target domains known to mitigate suicide risk are needed during this critical transition period. This proposal would bridge this important healthcare gap using STEP-Home-SP, a transdiagnostic, non-stigmatizing, skills-based workshop. STEP-Home-SP will provide Veterans with suicide prevention education, skills to improve transition, support to access VA care, and a platform to decrease social isolation early in their military to civilian transition, thereby reducing suicide risk downstream.",[105,29,32,106,107,108],"TBI","PTSD","Transdiagnostic","Anger",[32,105,107,110,29,106,111],"Intervention","Reintegration","2026-03-04",{"date":114,"type":45},"2026-03-06",{"date":116,"type":45},"2024-03-01",{"date":118,"type":21},"2027-05-31",{"name":89,"class":90},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":53},"100609687","stepped-care-intervention-of-music-and-imagery-to-assess-relief-scimitar-trial-100609687","NCT07217821","Stepped-Care Intervention of Music and Imagery to Assess Relief (SCIMITAR) Trial","SCIMITAR","Inclusion Criteria:\n\n* musculoskeletal pain in the low back, cervical spine, or extremities (hips, knees, or shoulders) for ≥ 3 months\n* at least moderate pain severity, defined as a PEG score ≥ 4 on a 0 (no pain) to 10 (worst pain)\n* access to computer, tablet, or smartphone\n* ability to pass a technology assessment\n\nExclusion Criteria:\n\n* Past month hospitalization for medical or psychiatric illness\n* housing insecurity\n* suicidal ideation with current intent\u002Fplan\n* hearing or cognitive impairment that may interfere with music listening or abstract thinking needed for imagery work\n* currently receiving music therapy services",{"count":128,"type":21},180,[24],"Th Stepped-Care Intervention of Music and Imagery to Assess Relief (SCIMITAR) Trial. SCIMITAR builds on our pilot study, the Feasibility and Acceptability of Music Imagery and Listening Interventions for Analgesia (FAMILIA), which demonstrated that telehealth delivery of music listening (ML) and music imagery (MI) interventions is feasible and acceptable to Veterans with chronic musculoskeletal pain. SCIMITAR leverages what we learned from FAMILIA into a fully powered trial, harnessing the benefits of sequential ML and MI into a stepped-care, music therapy intervention via telehealth for Veterans needing relief from pain.",[132,32,133],"Chronic Musculoskeletal Pain","Music Therapy",[135,136,137,138,139],"chronic pain","veterans","musculoskeletal pain","music therapy","clinical trial","2025-10-15",{"date":142,"type":45},"2025-10-16",{"date":144,"type":45},"2023-08-30",{"date":146,"type":21},"2026-04-30",{"name":148,"class":52},"Henry M. Jackson Foundation for the Advancement of Military Medicine",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":53},"100545382","phase-1-warrior-care-cannabis-behavioral-health-100545382","NCT06381180","Warrior CARE: Cannabis Behavioral Health","Wayne Warrior CAnnabis Research and Education: Cannabis and Behavioral Health","CBH","Inclusion Criteria:\n\n* a healthy veteran who has served in a branch of the US armed forces\n* report using cannabis within the past year\n* currently meet DSM-5 criteria for PTSD and a score of 25 or greater on the CAPS-5 (the anchor, or index, trauma does not have to be related to military service)\n* between the ages of 19-69 years old\n* not seeking treatment for Cannabis Use Disorder\n* stable (i.e., under the care of a physician or therapist and not experiencing acute symptoms) on psychotropic medications and\u002For psychotherapy before the study begins (participants can be in treatment for PTSD)\n* agree to adhere to study procedures\n\nExclusion Criteria:\n\n* pregnant, lactating, or heterosexually active women and not using medically approved birth control\n* current or past bipolar or psychotic disorder as determined using the SCID-5\n* at immediate high risk for suicide based on the C-SSRS\n* current SUD other than Nicotine Use Disorder and Alcohol Use Disorder (mild or moderate)\n* allergies and\u002For other contradictions for using cannabis\n* any clinically significant medical problems\n* systolic\u002Fdiastolic BP \\>140\u002F90 mmHg or systolic BP \\\u003C95 mmHg\n* elevated liver function tests\n* exhibit cognitive impairment (\\\u003C80 IQ)\n* enrolled in another clinical trial or have received any drug as part of a research study within 30 days of dosing\n* used a prescription medication (with the exception of birth control) within 14 days of study entry that in the opinion of the medically responsible investigator will interfere with the safety of the participant or the study results\n* unable to provide informed consent","19 Years","69 Years",{"count":160,"type":21},500,[162,163],"PHASE1","PHASE2","This study is a randomized, controlled clinical trial to examine the therapeutic potential of cannabinoids for treating veterans with PTSD and suicidal ideation.",[166,167,168,32,169],"Post Traumatic Stress Disorder","Cannabis Use","Suicide","Marijuana","2025-09-23",{"date":172,"type":45},"2025-09-29",{"date":174,"type":21},"2025-09-22",{"date":176,"type":21},"2030-12-31",{"name":178,"class":52},"Wayne State University",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":196,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":53},"100573464","nonendoscopic-screening-for-barretts-esophagus-in-veterans-without-chronic-reflux-100573464","NCT06746623","Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux","Nonendoscopic Screening for Barrett's Esophagus and Esophageal Cancer in At-Risk Veterans Without History of Chronic Gastroesophageal Reflux","Inclusion Criteria:\n\n* Patients without history of chronic GERD who meet criteria for upper endoscopic screening for BE will be accrued35.\n\n  1. Adults \\> 40 and \\\u003C 85 years old who have no prior EGD and can provide informed consent\n  2. Absence of chronic GERD symptoms (absence of weekly heartburn or regurgitation, not on medications for GERD), and are:\n\n     a. Meet ACG\u002FAGA Clinical Guideline criteria for BE screening. Eligible subjects will have at least three additional risk factors for BE (white race, obesity defined as BMI \\> 30, male gender, current smoker or smoking history \\> 10 pack years, family history of Barrett's esophagus or EAC central obesity (waist size \\> 35 inches for women and \\> 40 inches for men), white race, male sex, confirmed history of BE\u002FEAC in at least two family members, with one a first degree relative).\n  3. No known coagulopathy, no known esophageal varices, not on chronic anticoagulation therapy, and have:\n  4. No significant dysphagia or odynophagia\n\nExclusion Criteria:\n\n* Exclusion Criteria\n\n  1. History of prior EGD procedure in past ten years\n  2. Inability to provide written informed consent\n  3. History of weekly or more frequent heartburn or regurgitation for five or more years\n  4. On anti-coagulant drug(s) that cannot be temporarily discontinued or coagulopathy with INR \\> 1.5\n  5. Known history of esophageal varices or esophageal stricture\n  6. Any contraindication, as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and\u002For having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and\u002For esophageal ulceration\n  7. History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills\n  8. Oropharyngeal tumor\n  9. History of esophageal or gastric surgery, with exception on uncomplicated recent surgical fundoplication procedure with documented normal acid exposure time (AET) percent (AET \\\u003C4%)\n  10. History of myocardial infarction or cerebrovascular accident within past 6 months","40 Years","85 Years",{"count":63,"type":21},[24],"The veteran population is at increased risk for EAC and its precursor lesion, Barrett's esophagus (BE), due to increased prevalence of disease risk factors compared to the general population. BE is traditionally diagnosed only when patients undergo endoscopy with biopsies. However, due to the high cost of endoscopy and the lack of studies proving efficacy of screening, endoscopy to screen for BE is not routinely recommended. A simpler screening procedure similar to a pap smear would be an ideal way to sample the esophageal tissue for cancer and its precursor condition, BE. This study proposes a non-endoscopic detection method administered in outpatient offices which would increase subsequent endoscopic detection of BE. The study team will be enrolling veterans who do not have history of gastroesophageal reflux but have multiple risk factors for esophageal adenocarcinoma.",[192,193,32,194,195],"Obese Patients","Tobacco Use","Family History of Esophageal Cancer","Barrett Esophagus",[197,198,199],"Non-endoscopic screening","esophagus","Barrett","2025-06-03",{"date":202,"type":45},"2025-06-05",{"date":204,"type":45},"2025-04-11",{"date":206,"type":21},"2028-12-31",{"name":208,"class":90},"Louis Stokes VA Medical Center",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":256,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":53},"100565622","phase-1-evaluating-the-efficacy-and-safety-of-prosomnia-sleep-therapy-in-patients-with-sleep-deprivation-and-chronic-insomnia-100565622","NCT06644573","Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia","PSHW","By adhering to the following criteria, the study aims to select a population that can safely undergo the PROSOMNIA Sleep therapy and for whom the therapy is most likely to be beneficial, ensuring the reliability and validity of the study outcomes.\n\nINCLUSION CRITERIA:\n\n1. Age Range: 18-65 years of age Reason: This age range includes adults who are most likely to benefit from the PROSOMNIA Sleep therapy and who can provide informed consent. It also excludes children and older adults who may have different physiological responses or additional health risks.\n2. Diagnosed or Undiagnosed Chronic Insomnia:\n\n   Reason: Included subjects have a consistent pattern of sleep disturbances that PROSOMNIA Sleep Therapy aims to treat.\n3. Diagnosed or Undiagnosed Sleep Deprivation:\n\n   Reason: Includes individuals who are not getting enough sleep quantity, which is a key condition that the PROSOMNIA Sleep Therapy aims to address.\n4. Diagnosed or Undiagnosed REM Sleep Inconsistencies:\n\n   Reason: Includes individuals who are not getting enough sleep quality and those with specific REM sleep phase issues that the PROSOMNIA Sleep Therapy is designed to improve.\n5. Failure to Respond to Conventional Sleep Treatments:\n\n   Reason: Focuses on subjects who have not found relief from existing sleep therapies, ensuring that the study population represents those in need of alternative solutions.\n6. Ability to Provide Informed Consent:\n\nReason: Ensures that participants understand the study and agree to participate voluntarily.\n\nEXCLUSION CRITERIA:\n\n1. Severe Obesity (BMI \\> 40):\n\n   Reason: Severe obesity can increase the risk of complications with anesthesia and may affect sleep patterns in ways that could confound study results.\n2. Cardiovascular Conditions:\n\n   Reason: Patients with significant heart conditions are at higher risk for complications during anesthesia.\n3. Neurological Disorders:\n\n   Reason: These diagnosed conditions and medications such as epilepsy could interfere with sleep patterns and responses to sleep therapy.\n4. Other Health Conditions Contraindicating Anesthesia:\n\n   Reason: Includes any condition that would make the use of anesthesia unsafe.\n5. Greater than ASA II Status:\n\n   Reason: The American Society of Anesthesiologists (ASA) physical status classification system classifies patients based on their pre-anesthesia medical conditions. Excluding those above ASA II ensures that only patients with mild systemic disease are included, to minimize risks.\n6. Current Use of Prohibited Medications:\n\n   Reason: Medications that could interfere with the combined use of anesthesia including, but not limited to sedatives and hypnotics; such as benzodiazepines, Z-drugs and barbiturates.\n7. Pregnancy or Breastfeeding:\n\nReason: Ensures the safety of the fetus or infant, as the effects of the PROSOMNIA Sleep therapy on pregnancy or lactation are unknown.",{"count":217,"type":21},100,[162],"This clinical trial aims to evaluate the safety and efficacy of PROSOMNIA Sleep Therapy (PSTx) for individuals suffering from chronic insomnia, sleep deprivation, and REM sleep disorders. Chronic insomnia, characterized by difficulty falling or staying asleep, significantly affects patients and quality of life, mood, and cognitive function. REM sleep disorders, in which the body struggles to enter or maintain restful REM sleep, can worsen these issues. The trial introduces a novel therapy using anesthesia-induced sleep, targeting sleep homeostasis and improving sleep architecture.\n\nObjectives: The primary goals of the trial are to determine:\n\n1. Whether PROSOMNIA Sleep Therapy increases the quality of REM sleep.\n2. Whether PSTx increases the duration of REM and\u002For NREM sleep.\n3. Whether PSTx decreases the time it takes participants to fall asleep (sleep onset latency).\n\nParticipants will receive ONE (1) PROSOMNIA Sleep Therapy session lasting between 60-120 minutes. Each session uses Diprivan\u002FPropofol to induce sleep, and is monitored via an EEG to ensure proper sleep stages, particularly REM sleep.\n\nParticipant Criteria:\n\nInclusion: Adults aged 18-65 with diagnosed or undiagnosed chronic insomnia or sleep deprivation.\n\nExclusion: Patients with severe obesity, significant cardiovascular, neurological, or psychiatric conditions, or those with an ASA status above II.\n\nStudy Design: This trial is non-randomized, single-arm and open-label, with all participants receiving the PSTx. The trial does not include a comparison group, as the focus is on evaluating the immediate, direct effects of the therapy.\n\nParticipants will undergo continuous EEG monitoring during therapy sessions, allowing researchers to track brain activity and sleep stages in real-time. This method ensures that sleep cycles, particularly REM sleep, are optimized for therapeutic benefit.\n\nTherapy Methodology:\n\nPROSOMNIA Sleep Therapy leverages anesthesia to mimic natural sleep patterns and enhance the efficiency of REM sleep. Diprivan\u002FPropofol is used to induce REM sleep, while EEG monitoring tracks and maintains proper sleep architecture throughout the session. The therapy promotes the clearance of adenosine, a compound that builds up during wakefulness and drives the need for sleep. Adenosine is cleared during REM sleep, reducing sleep pressure and improving cognitive function.\n\nOutcome Measures:\n\nPrimary Outcomes: Researchers will measure the increase in REM sleep duration, improvement in sleep quality (via self-reported questionnaires), and a reduction in sleep onset latency.\n\nSecondary Outcomes: These include changes in mood, cognitive function, and blood serum uric acid levels. Patient-reported outcomes will also be tracked through tools like the PROSOMNIA Sleep Quiz, which is specifically designed for PSTx.\n\nSignificance: Chronic insomnia and REM sleep disorders affect millions globally, leading to cognitive impairment, mood disturbances, and poor overall health. Traditional treatments, including pharmacological approaches and Cognitive Behavioral Therapy for Insomnia (CBT-I), often provide suboptimal results for many individuals. PSTx offers a novel, therapeutic approach to restoring sleep balance and enhancing the overall quality of sleep, particularly for those who have not responded to conventional treatments.\n\nStudy Process:\n\nRecruitment and Baseline Assessments: Participants undergo a comprehensive sleep assessment, including sleep questionnaires and polysomnography, to establish a baseline for sleep quality and duration. Blood serum uric acid levels will also be measured to track any biochemical changes due to therapy.\n\nTherapy Sessions: Only one (1) PROSOMNIA Sleep Therapy session will be administered, with the session lasting between 60-120 minutes. Diprivan\u002FPropofol is used to induce sleep, and EEG will monitor brain activity to ensure the proper balance of sleep stages.\n\nPost-Therapy Follow-up: Follow-up assessments will occur at 24 hours, 7 days, and 30 days post-treatment. Researchers will analyze the therapy effects on REM sleep, mood, cognitive function, and other health indicators.\n\nPotential Implications: If successful, this trial could revolutionize how we treat sleep disorders by targeting the underlying mechanisms of sleep pressure and REM sleep disruption. PROSOMNIA Sleep Therapy may offer a safe, effective, and immediate alternative for patients who have exhausted other treatment options.\n\nKey Concepts:\n\nHomeostatic sleep drive, (Process S), caused by adenosine buildup during wakefulness, is disrupted by chronic insomnia. This impacts cognitive function health and recovery. Anesthesia-induced REM sleep via PSTx helps regulate this homeostatic sleep stage, offering deeper and more restorative sleep compared to other sleep therapies. The study uses statistical methods like ANOVA and Chi-square to measure outcomes.",[221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,106,246,247,248,249,250,32,251,252,253,254,255],"Chronic Insomnia","Sleep Deprivation","REM Behavior Disorder","REM Sleep Behavior Disorder","REM Sleep Measurement","Insomnia","Insomnia Related to Specified Disorder","Insomnia Due to Other Mental Disorder","Insomnia Comorbid to Psychiatric Disorder","Insomnia Due to Anxiety and Fear","Insomnia Related to Another Mental Condition","Insomnia Disorders","Idiopathic Hypersomnia","Sleep Disorders, Circadian Rhythm","Post Trauma Nightmares","PTSD - Post Traumatic Stress Disorder","Sleep Quality","Anesthesia","Anxiety","Depression","Mental Health","Alzheimer Disease or Associated Disorder","Parkinsons","Circadian Rhythm","Circadian Dysregulation","Post-Traumatic","Post-Traumatic Stress Disorder Complex","Military Combat Stress Reaction","Sleep","Military Activity","Shift Work Sleep Disorder","Menopause Related Conditions","Pain","Cancer Pain","Athletes",[257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,226,222,275,233,276,106,241,239,240],"SLEEP","PROSOMNIA Sleep","PROSOMNIA Sleep Therapy","PSTx","PROSOMNIA","Anesthesia Sleep","REM Sleep","REM Sleep Therapy","PROSOMNIA Sleep Health","PROSOMNIA Sleep Wellness","PROSOMNIA Sleep Treatment","Nyree","Nyree Penn","Propofol","Propofol Sleep","Diprivan","Diprivan Sleep","PROSOMNIA Sleep Health and Wellness","IH","Sleep Debt","2025-05-27",{"date":279,"type":45},"2025-05-28",{"date":281,"type":21},"2025-11-01",{"date":283,"type":21},"2026-05-01",{"name":269,"class":285},"INDUSTRY"]